Drug intelligence / Profile preview

EME-17

Development stage: Preclinical
Lead developer: Epsilon Molecular Engineering
Modality: Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

EME-17 is a preclinical-stage single-domain antibody (VHH nanobody) being developed by Epsilon Molecular Engineering (EME) for cancer immunology (immuno-oncology). The drug candidate was identified using EME's proprietary evolutionary molecular engineering platform, which utilizes cDNA display technology and the PharmaLogical® Library (a humanized VHH artificial library) to screen and select high-affinity VHH antibodies. As of 2026, EME-17 is in preclinical development, with its specific biological target remaining undisclosed.

Beyond the preview

Go deeper on EME-17.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EME-17.

Explore the full profile